Study shows low rate of late lumen loss with bioresorbable DESolve device

<P>&nbsp;Contact: Isabelle Uzielli<BR>iuzielli@europcr.com<BR>33-612-233-3492<BR>European Society of Cardiology <BR>
<P>21 May 2013, Paris, France: The DESolve bioresorbable coronary scaffold system achieves good efficacy and safety with low rates of late lumen loss and major coronary adverse events at six months, show first results from the pivotal DESolve Nx trial reported at EuroPCR 2013 today.
<P>DESolve (Elixir Medical Corporation) is the

Read more ...